Author:
Messina Gaetana,Bove Mary,Opromolla Giorgia,Di Filippo Vincenzo,Pirozzi Mario,Caterino Marianna,Facchini Sergio,Zotta Alessia,Vicidomini Giovanni,Santini Mario,Fiorelli Alfonso,Ciardiello Fortunato,Fasano Morena
Abstract
Lung cancer is the leading cause of cancer-related death and the most diagnosed cancer. The treatment of Non-Small Cell Lung Cancer (NSCLC) depends on clinical staging. Surgical radical resection is recommended for patients with stage 1 or 2 of disease and represents the treatment of choice. In the last decades, the surgical approach for lung cancer changed moving from an open approach to a minimally invasive approach, represented by Video Assisted Thoracic Surgery (VATS) and Robot-Assisted Thoracic Surgery (RATS). In this chapter, we illustrate the characteristics of lung cancer, the diagnosis, the classification, the staging and the preoperative evaluation. Then we focus on the surgical treatment of lung cancer and on how it has changed during the years. We explain the open approach represented by the traditional posterolateral thoracotomy and by the muscle-sparing thoracotomy. We illustrate VATS approach and evolution: from the hybrid approach to the pure VATS that can be triportal, biportal or even uniportal. Then, we focus on RATS approach, characterized by the use of multiple ports in the same intercostal space and how it evolved toward the uniportal approach. The objective is to combine the advantage of uniportal VATS (lower postoperative pain, enhanced recovery) and RATS (better visualization, more degrees of movements).
Reference48 articles.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022;72:7-33
2. Howlader N. SEER Cancer Statistics Review, 1975-2018, based on November 2020 SEER data submission, Bethesda, MD: National Cancer Institute, April 2021. [Online]. Available from: https://seer.cancer.gov/csr/1975_2018/
3. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: Looking to the future. Journal of Clinical Oncology. 2005;23(31):75-85
4. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update. Journal of Thoracic Disease. 2010;2(1):48-51
5. National Lung Screening Trial Research Team, Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, et al. The National Lung Screening Trial: Overview and study design. Radiology. 2011;258:243-253